Literature DB >> 16205070

Localization of IL-8 and complement components in lesional skin of psoriasis vulgaris and pustulosis palmaris et plantaris.

Maki Ozawa1, Tadashi Terui, Hachiro Tagami.   

Abstract

BACKGROUND: Munro's microabscesses are a characteristic histopathologic feature of psoriasis vulgaris; however, the pathomechanisms underlying the migration of transepidermal leukocytes (PMNs) have not been fully elucidated yet. OBJECTIVE AND METHODS: Since the lesional scale extracts contain potent chemoattractants, such as IL-8 and C5a fragments, we studied their location in the lesions of psoriasis vulgaris and PPP with immunohistochemical techniques.
RESULTS: Localization of IL-8 was not detected in the subcorneal keratinocytes but was demonstrated only in the basal keratinocytes together with migrating PMNs. In contrast, the presence of a complement fragment, C3b, was observed on the cell membranes of subcorneal keratinocytes, suggesting that these were the sites of complement activation.
CONCLUSION: Such distinct localization of IL-8 and complement components suggests that the intraepidermal migration of PMNs takes place first according to the concentration gradient of IL-8, and thereafter they are guided by complement components to the final destination, the subcorneal portion of the lesional skin. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16205070     DOI: 10.1159/000087019

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  9 in total

1.  Concomitant activation of P2Y(2) and P2Y(6) receptors on monocytes is required for TLR1/2-induced neutrophil migration by regulating IL-8 secretion.

Authors:  Fethia Ben Yebdri; Filip Kukulski; Alain Tremblay; Jean Sévigny
Journal:  Eur J Immunol       Date:  2009-10       Impact factor: 5.532

2.  Up-regulation of CC chemokine receptor 6 on tonsillar T cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris.

Authors:  T Yoshizaki; N Bandoh; S Ueda; H Nozawa; T Goto; K Kishibe; M Takahara; Y Harabuchi
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

3.  Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis.

Authors:  Masamoto Murakami; Takaaki Kaneko; Teruaki Nakatsuji; Kenji Kameda; Hidenori Okazaki; Xiuju Dai; Yasushi Hanakawa; Mikiko Tohyama; Akemi Ishida-Yamamoto; Koji Sayama
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

Review 4.  Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments.

Authors:  Magdalena Misiak-Galazka; Joanna Zozula; Lidia Rudnicka
Journal:  Am J Clin Dermatol       Date:  2020-06       Impact factor: 7.403

5.  Apremilast Microemulsion as Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation.

Authors:  Paulo Sarango-Granda; Marcelle Silva-Abreu; Ana Cristina Calpena; Lyda Halbaut; María-José Fábrega; María J Rodríguez-Lagunas; Natalia Díaz-Garrido; Josefa Badia; Lupe Carolina Espinoza
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-21

6.  A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis.

Authors:  Robert Bissonnette; Catherine Maari; Athanasios Tsianakas; DeAnne Reid; Sara McCutchan; Scott Baumgartner; James Mackay; Nihar Bhakta
Journal:  Dermatol Ther (Heidelb)       Date:  2021-10-30

Review 7.  Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective.

Authors:  Toshiyuki Yamamoto
Journal:  Clin Pharmacol       Date:  2021-06-23

Review 8.  Promising new treatments for psoriasis.

Authors:  Sarah Dubois Declercq; Roxane Pouliot
Journal:  ScientificWorldJournal       Date:  2013-07-01

9.  Eccrine sweat contains IL-1α, IL-1β and IL-31 and activates epidermal keratinocytes as a danger signal.

Authors:  Xiuju Dai; Hidenori Okazaki; Yasushi Hanakawa; Masamoto Murakami; Mikiko Tohyama; Yuji Shirakata; Koji Sayama
Journal:  PLoS One       Date:  2013-07-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.